[Geneva, Switzerland and Waltham, USA – 19 August 2019]
The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organisation developing new treatments for drug resistant infections, and Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today jointly announced the initiation of a global phase 3 pivotal trial of zoliflodacin. Zoliflodacin is a novel, first-in-class oral antibiotic being developed for the treatment of gonorrhoea.
[Geneva – 19 August 2019]
GARDP and FIND welcome the Australian Minister for Education’s announcement of $5m to establish an Australian Research Council (ARC) Research Hub to Combat Antimicrobial Resistance, which will be led by the Kirby Institute.
[Geneva – 26 June 2019]
GARDP calls upon the global community to work with it to develop and deliver 5 new treatments by 2025 to address the most urgent public health needs
Today GARDP announces its ‘5 BY 25’ goal to deliver five new treatments in response to the growing global threat of antimicrobial resistance (AMR). GARDP’s five treatments will focus on the priority bacterial pathogens identified by the World Health Organization (WHO).
[Geneva – 23 May 2019]
GARDP is pleased to announce funding of €400,000 from the Government of the Principality of Monaco. This grant is being formalized at the 2019 World Health Assembly, where antimicrobial resistance (AMR) is a priority topic.
[Geneva – 23 May 2019]
DNDi and GARDP welcome the adoption of the resolution on AMR and call for continued political commitment at the highest level, including at the UN High-Level Meeting on Universal Health Coverage at the UN General Assembly in September.
[Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019]
GARDP is partnering with Calibr, HIPS, and CO-ADD in its efforts to develop and ensure new antibiotics are globally available to all patients who need them.
[Geneva – 2 April 2019]
GARDP is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.
[Geneva/Hamburg – 19 March 2019]
GARDP and Evotec AG are announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance (AMR). By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections.
[Geneva/Padova – 4 March 2019]
GARDP and Penta, the paediatric infectious diseases research network, have joined forces to tackle drug-resistant infections in children. The strategic collaboration aims to accelerate paediatric development of antibiotic treatments including: clinical trials designed to meet regulatory requirements; and trials with a focus on public health interventions to inform treatment guidelines.
[Geneva – 31 January 2019]
DNDi and GARDP call for move from discussion of principles to practical guidance on ensuring access and stewardship of new and existing antibiotics at AMR discussion.
[Geneva – 4 January 2019]
Funding supports developing antibiotics for important global health priorities
GARDP is pleased to receive a EUR 1.5 million investment from the German Federal Ministry of Health (MOH). This funding is already contributing to GARDP’s efforts to develop antibiotics for drug-resistant infections including sexually-transmitted infections and newborns with sepsis – both important global health priorities. The investment also supports GARDP’s growth as its incubation period, hosted by DNDi, comes to an end.